Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241319 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
A Phase 3 study, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00241319 is a Phase 3 study that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT00241319, a Phase 3 study, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
Interventions
- DRUG R89674 (generic name not yet established)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241319
The ClinicalTrials.gov registry entry for NCT00241319 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R89674 (generic name not yet established) is the first listed.
NCT00241319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241319 about?
NCT00241319 is a clinical study titled "Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis". The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
What is the current status of trial NCT00241319?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2005-10.
What interventions are being tested in trial NCT00241319?
The interventions under investigation include: R89674 (generic name not yet established) (DRUG).
Who is sponsoring clinical trial NCT00241319?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.